Effectiveness of fosfomycin versus nitrofurantoin in Dutch risk groups with cystitis: a pilot study (Uri-weg study) - Uri-weg study

Streeklaboratorium voor de volksgezondheid Kennemerland0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Patients presenting to their GP with symptoms of cystitis belonging to a risk group (according to the NHG standard in 2013) without signs of tissue invasion, and have an indication for antibiotic treatment according to the GP. Dutch defined risk groups are defined by males, pregnant females, patients with diabetes mellitus, impaired immunity, abnormalities of the renal or urinary tract, neurological bladder dysfunction and/or an indwelling urinary catheter.

•Patients with known renal dysfunction(s) (MDRD < 60 ml/min).
•Patient is known with an uropathogen isolated in the past 12 months with resistance towards nitrofurantoin and/or fosfomycin.
•Patient is known with earlier complications towards nitrofurantoin and/or fosfomycin such as allergic reactions, hypersensitivity peripheral neuropathy and/or lung and liver reactions.
•Patients known with Glucose-6-phosphate dehydrogenase deficiency, fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase insufficiency, acute porphyria or gout.
•Patients using other antibiotics and/or using alkalizing agents.
•For pregnant women: is in the first trimester of pregnancy (week 1 to 13) or in the period of delivery (after the first contractions).
•Patients who refuse or are unable to give informed consent.

发起方

Streeklaboratorium voor de volksgezondheid Kennemerland